Home・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

2.97 -1

Buy Sell

Overview

Share price change

24h

Current

Min

2.96

Max

2.99

Key metrics
By Trading Economics
Income	-9.4M -118M
Sales	-29M 6.5M
EPS	-0.22
Profit margin	-1,815.575
Employees	600
EBITDA	-13M -102M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+149.32% upside

Dividends
By Acuity
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-334M 1.5B
Previous open	3.97
Previous close	2.97

News Sentiment

By Acuity

50%

163 / 340 Healthcare

Recursion Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jul 2026, 23:11 UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

23 Jul 2026, 19:16 UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

22 Jul 2026, 23:36 UTC

Recursion Pharmaceuticals Inc. shares are near unchanged in after-market hours. The stock remains below its 20-day moving average amid rising crude oil prices.

21 Jul 2026, 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

20 Jul 2026, 19:46 UTC

Correlated Moves

Recursion Pharmaceuticals is declining, continuing a trend from previous sessions, amid broader declines in the ARK Genomic Revolution ETF and Russell 2000 Index.

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

149.32% upside

12 Months Forecast

Average 7.38 USD 149.32%

High 10 USD

Low 5.5 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

163 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.